Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quetiapine + sodium valproate
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quetiapine + sodium valproate is a **combination of two pharmaceutical drugs** commonly used in psychiatry. **Quetiapine** is an atypical antipsychotic primarily indicated for schizophrenia, bipolar disorder, and as adjunct therapy in major depressive disorder[2][6]. **Sodium valproate** (valproic acid) is a mood stabilizer, anticonvulsant, and is indicated for epilepsy, bipolar disorder (manic and mixed episodes), and migraine prophylaxis. **This combination is used as adjunctive therapy, mostly in the management of acute mania or mixed episodes in bipolar I disorder and has been trialed in Alzheimer's disease for behavioral symptoms**[1][7]. *Quetiapine* acts mainly through antagonism of dopamine D2 and serotonin 5-HT2A receptors, while *sodium valproate* increases GABA levels and modulates neuronal excitability. **There is evidence that the combination is effective for psychiatric symptoms but may result in additive side effects such as CNS depression (drowsiness, confusion, dizziness)**[3][5][7].
- Brand names
- None found specific to the combination
- Other names
- quetiapine and valproate sodiumquetiapine and valproic acid
02
Targets
DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)HTR2A (Serotonin receptor 5-HT2A)NaV (Voltage-gated sodium channels)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on quetiapine + sodium valproate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quetiapine + sodium valproate.